Developer docs
API playgroundTry for free, no card

Search company profiles

Clade Therapeutics

Full company profile

uuid0000rrh

Namestring
Clade Therapeutics
Websiteurl
cladetx.com
Company typeenum
Private
Founded yearint
2020
Short descriptiontext

Clade Therapeutics is a Cambridge, Massachusetts biotech developing off-the-shelf, stem cell-based cell therapies for cancer using proprietary immune cloaking technology and gamma/delta T-cell receptor platforms acquired from Gadeta B.V.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
stem cell therapy, cell therapy platform, cancer immunotherapy, T cell receptor, cell engineering
Industry4 codes
1Cell Therapy Developers (Allogeneic/Off-the-shelf)
CodeHLAAABABPrimaryYes
2Stem Cell Therapies (MSC/iPSC/HSC-derived)
CodeHLAAABAEPrimaryNo
3Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
CodeHLAAABALPrimaryNo
4CAR-T & TCR-T Therapies
CodeHLAAABACPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Cancer Immunotherapy
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Clade Therapeutics discovers and develops next-generation cell medicines using proprietary immune cloaking technology applied to stem cells, enabling off-the-shelf, scalable allogeneic therapies. The company also develops gamma/delta T-cell receptor (TCR) immunotherapies through its Gadeta B.V.-acquired platform for the treatment of cancer.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Stem Cell-Based Medicines Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Gadeta B.V.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-02
Description

Acquired by Clade Therapeutics, providing access to preclinical programs, TCR discovery engine, and cell enhancement technologies for developing gamma/delta T-cell receptor-based immunotherapies for cancer.

Peers10 records
1Allogene Therapeutics
TypeDirect peer
Description

Allogene is a leading developer of allogeneic, off-the-shelf CAR-T cell therapies. Like Clade, it is pursuing scalable, off-the-shelf alternatives to autologous cell therapies for cancer, making it a directly comparable peer in the allogeneic cell therapy space.

2Fate Therapeutics
TypeDirect peer
Description

Fate Therapeutics develops off-the-shelf, iPSC-derived cell therapies including NK and T-cell candidates for cancer. Its iPSC-based off-the-shelf platform is closely analogous to Clade's stem cell-based approach to scalable cell medicines.

3Century Therapeutics
TypeDirect peer
Description

Century Therapeutics is developing allogeneic, iPSC-derived cell therapies engineered to overcome immune rejection. Its platform and goals around off-the-shelf, immune-evasive cell medicines closely parallel Clade's immune cloaking strategy.

4Adaptimmune Therapeutics
TypeDirect peer
Description

Adaptimmune specializes in TCR-based cell therapies for solid tumors, including gamma/delta TCR programs. Its TCR discovery and engineering capabilities overlap with the assets Clade acquired from Gadeta.

5CRISPR Therapeutics
TypeDirect peer
Description

CRISPR Therapeutics develops gene-edited cell therapies, including allogeneic CAR-T candidates. Its use of gene editing to enable off-the-shelf cell products positions it as a comparable peer in engineered allogeneic cell therapy development.

6Beam Therapeutics
TypeDirect peer
Description

Beam Therapeutics applies base editing to develop cell therapies, including allogeneic CAR-T programs. Its gene editing-enabled cell therapy approach overlaps with Clade's engineering-driven strategy for next-generation cell medicines.

7Atara Biotherapeutics
TypeDirect peer
Description

Atara develops allogeneic T-cell therapies, including EBV-specific T-cells and next-generation candidates. Its focus on off-the-shelf T-cell immunotherapies for cancer and viral diseases is directly comparable to Clade's gamma/delta TCR portfolio.

8Caribou Biosciences
TypeDirect peer
Description

Caribou Biosciences is developing allogeneic CAR-T cell therapies using its CRISPR-based chRDNA genome editing platform. Its pursuit of off-the-shelf, gene-edited cell therapies for oncology places it in the same competitive set as Clade.

9Cellectis
TypeDirect peer
Description

Cellectis is a clinical-stage biotech developing allogeneic CAR-T therapies using its proprietary TALEN gene editing platform. Its focus on gene-edited, off-the-shelf cell therapies for cancer closely mirrors Clade's platform approach.

10Bristol Myers Squibb
TypeBroad incumbent
Description

BMS is a major pharmaceutical company with an established cell therapy franchise (Breyanzi, Abecma) and a strategic investor in Clade. As a large incumbent in cell therapy commercialization, it serves as both a potential acquirer and a benchmark for industry economics.

Market position
Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clade Therapeutics

Cell Therapy / Cancer Immunotherapycladetx.com

Clade Therapeutics is a Cambridge, Massachusetts biotech developing off-the-shelf, stem cell-based cell therapies for cancer using proprietary immune cloaking technology and gamma/delta T-cell receptor platforms acquired from Gadeta B.V.

Clade Therapeutics firmographics

Firmographics
Name
Clade Therapeutics
Website
https://cladetx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Clade Therapeutics is a Cambridge, Massachusetts biotech developing off-the-shelf, stem cell-based cell therapies for cancer using proprietary immune cloaking technology and gamma/delta T-cell receptor platforms acquired from Gadeta B.V.
Ownership category
akta.pro rank

Clade Therapeutics industry classification

Industry
Product category
Cell Therapy / Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
akta.pro secondary industries
Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

  • Stem cell therapy
  • Cell therapy platform
  • Cancer immunotherapy
  • T cell receptor
  • Cell engineering

Where Clade Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Clade Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Clade Therapeutics product offering

Product offering

Core offering

Clade Therapeutics discovers and develops next-generation cell medicines using proprietary immune cloaking technology applied to stem cells, enabling off-the-shelf, scalable allogeneic therapies. The company also develops gamma/delta T-cell receptor (TCR) immunotherapies through its Gadeta B.V.-acquired platform for the treatment of cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stem Cell-Based Medicines Platform

Companies that use Clade Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Clade Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Clade Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gadeta B.V.coreStrategic or Co-development Partner · 2 October 2023Acquired by Clade Therapeutics, providing access to preclinical programs, TCR discovery engine, and cell enhancement technologies for developing gamma/delta T-cell receptor-based immunotherapies for cancer.

Scale indicators1 record

Clade Therapeutics competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Allogene is a leading developer of allogeneic, off-the-shelf CAR-T cell therapies. Like Clade, it is pursuing scalable, off-the-shelf alternatives to autologous cell therapies for cancer, making it a directly comparable peer in the allogeneic cell therapy space.
  • Fate Therapeutics: Fate Therapeutics develops off-the-shelf, iPSC-derived cell therapies including NK and T-cell candidates for cancer. Its iPSC-based off-the-shelf platform is closely analogous to Clade's stem cell-based approach to scalable cell medicines.
  • Century Therapeutics: Century Therapeutics is developing allogeneic, iPSC-derived cell therapies engineered to overcome immune rejection. Its platform and goals around off-the-shelf, immune-evasive cell medicines closely parallel Clade's immune cloaking strategy.
  • Adaptimmune Therapeutics: Adaptimmune specializes in TCR-based cell therapies for solid tumors, including gamma/delta TCR programs. Its TCR discovery and engineering capabilities overlap with the assets Clade acquired from Gadeta.
  • CRISPR Therapeutics: CRISPR Therapeutics develops gene-edited cell therapies, including allogeneic CAR-T candidates. Its use of gene editing to enable off-the-shelf cell products positions it as a comparable peer in engineered allogeneic cell therapy development.
  • Beam Therapeutics: Beam Therapeutics applies base editing to develop cell therapies, including allogeneic CAR-T programs. Its gene editing-enabled cell therapy approach overlaps with Clade's engineering-driven strategy for next-generation cell medicines.
  • Atara Biotherapeutics: Atara develops allogeneic T-cell therapies, including EBV-specific T-cells and next-generation candidates. Its focus on off-the-shelf T-cell immunotherapies for cancer and viral diseases is directly comparable to Clade's gamma/delta TCR portfolio.
  • Caribou Biosciences: Caribou Biosciences is developing allogeneic CAR-T cell therapies using its CRISPR-based chRDNA genome editing platform. Its pursuit of off-the-shelf, gene-edited cell therapies for oncology places it in the same competitive set as Clade.
  • Cellectis: Cellectis is a clinical-stage biotech developing allogeneic CAR-T therapies using its proprietary TALEN gene editing platform. Its focus on gene-edited, off-the-shelf cell therapies for cancer closely mirrors Clade's platform approach.

Broad incumbents

  • Bristol Myers Squibb: BMS is a major pharmaceutical company with an established cell therapy franchise (Breyanzi, Abecma) and a strategic investor in Clade. As a large incumbent in cell therapy commercialization, it serves as both a potential acquirer and a benchmark for industry economics.

Market position

Customer concentration

Clade Therapeutics social profiles

Digital presence

Clade Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clade Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Clade Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Clade Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clade Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clade Therapeutics

What does Clade Therapeutics do?

Clade Therapeutics discovers and develops next-generation cell medicines using proprietary immune cloaking technology applied to stem cells, enabling off-the-shelf, scalable allogeneic therapies. The company also develops gamma/delta T-cell receptor (TCR) immunotherapies through its Gadeta B.V.-acquired platform for the treatment of cancer.

Is Clade Therapeutics a public or private company?

Clade Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Clade Therapeutics founded?

Clade Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Clade Therapeutics based?

Clade Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Clade Therapeutics's main competitors?

Direct peers on record are Allogene Therapeutics, Fate Therapeutics, Century Therapeutics, Adaptimmune Therapeutics, CRISPR Therapeutics, Beam Therapeutics, Atara Biotherapeutics, Caribou Biosciences and Cellectis. Bristol Myers Squibb is listed as a broad incumbent.

Does Clade Therapeutics have an API?

No public API is recorded for Clade Therapeutics.

What industry is Clade Therapeutics in?

Clade Therapeutics's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaSmall-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics AcCentury Therapeutics announced a $35 million acquisition of Clade Therapeutics to expand its iPSC-based pipeline into autoimmune diseases and cancer, while simultaneously raising $60 million through a private placement to fund R&D. The company plans to initiate the CALiPSO-1 trial for systemic lupus erythematosus in the first half of 2024 and pursue additional regulatory filings for autoimmune indications this year.CenturytxCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsCentury Therapeutics announced a $60 million private placement led by Bain Capital Life Sciences and the acquisition of Clade Therapeutics to expand its pipeline in autoimmune diseases. The transaction strengthens Century's position in iPSC-derived cell therapy by adding three preclinical programs from Clade and enhancing its Allo-Evasion platform.BioSpaceCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsCentury Therapeutics announced a $60 million private placement led by Bain Capital Life Sciences to fund the expansion of its lead therapy, CNTY-101, into additional autoimmune disease indications. Concurrently, Century acquired Clade Therapeutics for approximately $35 million in upfront consideration to enhance its iPSC-derived cell therapy pipeline and technology platform.FierceBiotechFierce Biotech Layoff Tracker 2024: Layoffs at Denali; Cell therapy biotech Clade makes cutsIn February 2024, multiple biotech companies announced layoffs as part of strategic restructurings, including Denali Therapeutics and Clade Therapeutics, among others. Denali is reorganizing with a reduction of less than 10% of its workforce, while Clade's layoffs follow a recent change in leadership. The trend indicates a continued downturn in the biotech industry following a significant increase in layoffs in 2023, serving as a warning for the sector's future.SynconaltdClade Therapeutics Announces the Acquisition of Gadeta B.V.Clade Therapeutics has completed the acquisition of Gadeta B.V., integrating its proprietary gamma/delta TCR universal targeting platform technology into Clade's solid tumor pipeline. This strategic move expands Clade’s capabilities by adding preclinical cell therapy programs and a discovery engine to its existing cellular platform. The transaction makes Gadeta a wholly owned subsidiary, allowing Clade to develop more robust off-the-shelf stem-cell-based medicines.GlobeNewswireClade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell TherapyClade Therapeutics raised $87 million in Series A financing led by Syncona Ltd. with participation from LifeSci Venture Partners, Emerson Collective, and Bristol Myers Squibb. The funds will support development of its immune-cloaking stem cell platform for cancer therapeutics.BioSpaceClade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell TherapyClade Therapeutics secured an $87 million Series A financing round led by Syncona Ltd. with participation from LifeSci Venture Partners, Emerson Collective, and Bristol Myers Squibb. The proceeds will support the development of Clade’s proprietary platform for creating off-the-shelf, immune-cloaked stem cell-based medicines. This funding aims to accelerate the development of broadly accessible cancer therapeutics derived from engineered immune cells.GlobeNewswireClade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell TherapyClade Therapeutics secured an $87 million Series A financing round led by Syncona Ltd., with participation from LifeSci Venture Partners, Emerson Collective, and Bristol Myers Squibb. The funds will support the development of Clade’s proprietary platform for creating scalable, off-the-shelf stem cell-based medicines using immune cloaking technology. This investment aims to accelerate the development of cancer therapeutics derived from engineered induced pluripotent stem cells.